Charles Schwab
FBIO icon

Charles Schwab’s Fortress Biotech FBIO Stock Holding History

Charles Schwab’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,998
Closed -$16.5K – 3590
2023
Q2 		$16.5K Hold
1,998
– – ﹤0.01% 3579
2023
Q1 		$24.6K Hold
1,998
– – ﹤0.01% 3482
2022
Q4 		$19.6K Hold
1,998
– – ﹤0.01% 3505
2022
Q3 		$26K Hold
1,998
– – ﹤0.01% 3457
2022
Q2 		$26K Sell
1,998
-11,300
-85% -$167K ﹤0.01% 3500
2022
Q1 		$272K Buy
13,298
+864
+7% +$23.7K ﹤0.01% 3239
2021
Q4 		$467K Hold
12,434
– – ﹤0.01% 3170
2021
Q3 		$601K Buy
12,434
+586
+5% +$28.6K ﹤0.01% 3081
2021
Q2 		$635K Buy
11,848
+474
+4% +$28.6K ﹤0.01% 3089
2021
Q1 		$603K Buy
11,374
+34
+0.3% +$1.92K ﹤0.01% 3019
2020
Q4 		$540K Buy
11,340
+661
+6% +$28.6K ﹤0.01% 2963
2020
Q3 		$648K Buy
10,679
+334
+3% +$17K ﹤0.01% 2807
2020
Q2 		$416K Buy
+10,345
New +$384K ﹤0.01% 2903
2019
Q2 		– Sell
-5,044
Closed -$135K – 3231
2019
Q1 		$135K Buy
5,044
+1,251
+33% +$32.8K ﹤0.01% 3067
2018
Q4 		$49K Hold
3,793
– – ﹤0.01% 3132
2018
Q3 		$92K Hold
3,793
– – ﹤0.01% 3116
2018
Q2 		$170K Hold
3,793
– – ﹤0.01% 3079
2018
Q1 		$259K Hold
3,793
– – ﹤0.01% 2920
2017
Q4 		$228K Hold
3,793
– – ﹤0.01% 2953
2017
Q3 		$252K Hold
3,793
– – ﹤0.01% 2938
2017
Q2 		$271K Hold
3,793
– – ﹤0.01% 2906
2017
Q1 		$211K Hold
3,793
– – ﹤0.01% 2920
2016
Q4 		$154K Hold
3,793
– – ﹤0.01% 3006
2016
Q3 		$169K Hold
3,793
– – ﹤0.01% 2949
2016
Q2 		$154K Buy
+3,793
New +$177K ﹤0.01% 3005
2014
Q2 		– Sell
-2,553
Closed -$76K – 3103
2014
Q1 		$76K Hold
2,553
– – ﹤0.01% 3050
2013
Q4 		$101K Hold
2,553
– – ﹤0.01% 3055
2013
Q3 		$299K Hold
2,553
– – ﹤0.01% 2749
2013
Q2 		$313K Buy
+2,553
New +$376K ﹤0.01% 2712

Other funds holding FBIO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
SAM
Shikiar Asset Management New York $347M AUM 23.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab's FBIO Position: Q3 2023 in Review

Charles Schwab sold out of Fortress Biotech (FBIO) in Q3 2023, closing a stake of 1,998 shares — an estimated $16.5K sold.

Charles Schwab first reported a position in FBIO in Q2 2013 and held it in 29 quarters. The position peaked at $648K in Q3 2020. 48 funds tracked by Wall St. Rank hold FBIO as of Q3 2023.

  • Charles Schwab reported no remaining Fortress Biotech position as of Q3 2023 after selling out during the quarter.
  • Charles Schwab sold 1,998 Fortress Biotech shares in Q3 2023, an estimated $16.5K.
  • Charles Schwab first reported a position in Fortress Biotech in Q2 2013 and held it in 29 quarters.
  • Charles Schwab's Fortress Biotech position peaked at $648K in Q3 2020.
  • 48 funds tracked by Wall St. Rank held Fortress Biotech as of Q3 2023.

Based on Charles Schwab's 13F filing for Q3 2023, filed 8 Nov 2023.